FibroBiologics appoints former NASA astronaut Kathleen Rubins to board; director Matt Link resigns

FibroBiologics, Inc.

Matt Link resigned from the board effective July 2, 2026.
Kathleen Rubins appointed as Class III director effective July 8, 2026, term until 2029 annual meeting.
Rubins also appointed to Audit, Compensation, and Governance Committees.
Rubins is a retired NASA astronaut, microbiologist, and founding director of Trivedi Institute at University of Pittsburgh.
She previously served on FibroBiologics' Scientific Advisory Board since 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matt Link

Director

FBLG · FibroBiologics, Inc.

Effective: 2026-07-02
Filed: July 9, 2026, 9:31 AM ET

On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.

Appointed

Kathleen Rubins

Class III Director

FBLG · FibroBiologics, Inc.

Effective: 2026-07-08
Filed: July 9, 2026, 9:31 AM ET

On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matt Link resigned as Director at FibroBiologics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kathleen Rubins was appointed as Class III Director at FibroBiologics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.

View on SEC.gov

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-299290

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.